{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:28:32Z","timestamp":1793831312173,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.amjcard.2018.04.020","type":"journal-article","created":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:53:32Z","timestamp":1525136012000},"page":"483-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prediction of Extensive Myocardial Fibrosis in Nonhigh Risk Patients With Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"122","author":[{"given":"D.H. Frank","family":"Gommans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Etienne","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Fouraux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik-Jan","family":"Dieker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke","family":"Timmermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo L.M.","family":"Marcelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek W.A.","family":"Verheugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menko-Jan","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel J.M.","family":"Kofflard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-9140","authenticated-orcid":false,"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2018.04.020_bib0001","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0002","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/CIR.0b013e318223e2bd","article-title":"ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"124","author":"Gersh","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0003","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.amjcard.2014.01.435","article-title":"Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors","volume":"113","author":"Spirito","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0004","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.amjcard.2015.05.047","article-title":"Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy","volume":"116","author":"Maron","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0005","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jcmg.2016.01.032","article-title":"LGE means better selection of HCM patients for primary prevention implantable defibrillators","volume":"9","author":"Maron","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0006","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0007","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.amjcard.2017.01.032","article-title":"High-sensitivity troponin as a biomarker in heart rhythm disease","volume":"119","author":"McCarthy","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0008","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijcard.2016.05.031","article-title":"Clinical utility of natriuretic peptides and troponins in hypertrophic cardiomyopathy","volume":"218","author":"Kehl","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0009","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jacc.2008.04.047","article-title":"Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy","volume":"52","author":"Olivotto","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0010","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1253\/circj.CJ-15-1100","article-title":"Extent of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese hypertrophic cardiomyopathy patients","volume":"80","author":"Hen","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0011","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jacc.2007.11.071","article-title":"Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance","volume":"51","author":"Adabag","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0012","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.amjcard.2013.04.060","article-title":"Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy","volume":"112","author":"Kawasaki","year":"2013","journal-title":"Am J Card"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0013","article-title":"Predictive values of N-terminal Pro-B-type natriuretic peptide and cardiac troponin I for myocardial fibrosis in hypertrophic obstructive cardiomyopathy","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0014","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10554-010-9704-2","article-title":"Midregional pro-atrial natriuretic peptide: a novel marker of myocardial fibrosis in patients with hypertrophic cardiomyopathy","volume":"27","author":"Elmas","year":"2011","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0015","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cardfail.2010.07.245","article-title":"Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy","volume":"16","author":"Moreno","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0016","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10554-011-9876-4","article-title":"Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging","volume":"28","author":"Park","year":"2012","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0017","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.cardfail.2016.03.010","article-title":"Serum matrix metalloproteinases as quantitative biomarkers for myocardial fibrosis and sudden cardiac death risk stratification in patients with hypertrophic cardiomyopathy","volume":"22","author":"Munch","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0018","first-page":"w14285","article-title":"Elevated high-sensitivity troponin T levels are associated with adverse cardiac remodelling and myocardial fibrosis in hypertrophic cardiomyopathy","volume":"146","author":"Hasler","year":"2016","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0019","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jcmg.2016.02.031","article-title":"Prognostic value of LGE-CMR in HCM: a meta-analysis","volume":"9","author":"Weng","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0020","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/heartjnl-2016-309900","article-title":"High T2-weighted signal intensity is associated with elevated troponin T in hypertrophic cardiomyopathy","volume":"103","author":"Gommans","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0021","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.mri.2010.03.034","article-title":"Visual estimation of the extent of myocardial hyperenhancement on late gadolinium-enhanced CMR in patients with hypertrophic cardiomyopathy","volume":"28","author":"Doesch","year":"2010","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0022","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ejhf.669","article-title":"Variability of biomarkers in patients with chronic heart failure and healthy controls","volume":"19","author":"Meijers","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0023","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2015.02.008","article-title":"Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy","volume":"184","author":"Vergaro","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0024","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s10554-016-0958-1","article-title":"Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients","volume":"32","author":"Hu","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2017-000615","article-title":"Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy","volume":"4","author":"Ho","year":"2017","journal-title":"Open Heart"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0026","first-page":"361","article-title":"Soluble ST2 and myocardial fibrosis in 3T cardiac magnetic resonance","volume":"49","author":"Quick","year":"2015","journal-title":"Scand Cardiovasc J"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0027","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00380-013-0337-y","article-title":"Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts","volume":"29","author":"Hanatani","year":"2014","journal-title":"Heart Vessels"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0028","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejim.2011.08.022","article-title":"Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy","volume":"23","author":"Montoro-Garcia","year":"2012","journal-title":"Eur J Int Med"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0029","first-page":"344","article-title":"Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function","volume":"16","author":"Yakar Tuluce","year":"2015","journal-title":"Anatol J Cardiol"},{"key":"10.1016\/j.amjcard.2018.04.020_bib0030","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa1002659","article-title":"Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy","volume":"363","author":"Ho","year":"2010","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914918309433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914918309433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T14:13:07Z","timestamp":1536243187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914918309433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0002914918309433"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2018.04.020","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of Extensive Myocardial Fibrosis in Nonhigh Risk Patients With Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2018.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}